Extracorporeal elimination of TNF-α-producing CD14 dullCD16+ monocytes in leukocytapheresis therapy for ulcerative colitis

Takanori Kanai, Shin Makita, Takahiro Kawamura, Yasuhiro Nemoto, Daisuke Kubota, Kazuyoshi Nagayama, Teruji Totsuka, Mamoru Watanabe

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: In recent years leukocytapheresis using a leukocyte removal filter (known as lymphocytapheresis, LCAP) has been applied to the treatment of various autoimmune diseases including ulcerative colitis (UC). In the present study we aimed to clarify how LCAP therapy modifies inflammatory responses by modulating circulating TNF-α-producing monocytes. Methods: Mononuclear cells were obtained from blood before and after the first treatment, and the expression profiles of various immune cells (naive versus, memory, regulatory CD4+CD25bright versus non-regulatory CD4 +CD25- T cells, and CD14+CD16- versus CD14dullCD16+ monocytes) were assessed. To evaluate immunological differences between CD14+CD16- and CD14dullCD16+ monocytes, the expression of TNF-α, IL-6, IL-12, IL-10, IL-18, surface toll-like receptor 2 (TLR2), TLR4, and other activation markers including HLA-DR, CD80 and CD86, as well as cytokine profiles, were analyzed. Results: LCAP treatment selectively removed CD14 dullCD16+ monocytes, which preferentially produce TNF-α and IL-12 and express HLA-DR, CD80, CD86, and TLR2, compared with the major fraction of CD14+CD16- monocytes, which conversely produce a higher amount of IL-10. In addition, the CD4 +CD45RO+CD62L-/CD4+CD45RO +CD62L+ ratio was significantly lower after LCAP therapy. However, the CD4+CD25bright/total CD4+ ratio did not change. Conclusions: The present findings revealed the real target of proinflammatory CD14dullCD16+ monocytes removed during LCAP treatment of UC and that LCAP might be used as an extracorporeal anti-TNF-α therapy, expanding the clinical applications of this procedure to include the treatment of Crohn's disease.

Original languageEnglish
Pages (from-to)284-290
Number of pages7
JournalInflammatory Bowel Diseases
Volume13
Issue number3
DOIs
Publication statusPublished - 2007 Mar
Externally publishedYes

Fingerprint

Leukapheresis
Ulcerative Colitis
Monocytes
Toll-Like Receptor 2
HLA-DR Antigens
Therapeutics
Interleukin-12
Interleukin-10
Interleukin-18
Crohn Disease
Autoimmune Diseases
Interleukin-6
Leukocytes
Cytokines
T-Lymphocytes

Keywords

  • CD14CD16 monocytes
  • Leukocytapheresis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Extracorporeal elimination of TNF-α-producing CD14 dullCD16+ monocytes in leukocytapheresis therapy for ulcerative colitis. / Kanai, Takanori; Makita, Shin; Kawamura, Takahiro; Nemoto, Yasuhiro; Kubota, Daisuke; Nagayama, Kazuyoshi; Totsuka, Teruji; Watanabe, Mamoru.

In: Inflammatory Bowel Diseases, Vol. 13, No. 3, 03.2007, p. 284-290.

Research output: Contribution to journalArticle

Kanai, Takanori ; Makita, Shin ; Kawamura, Takahiro ; Nemoto, Yasuhiro ; Kubota, Daisuke ; Nagayama, Kazuyoshi ; Totsuka, Teruji ; Watanabe, Mamoru. / Extracorporeal elimination of TNF-α-producing CD14 dullCD16+ monocytes in leukocytapheresis therapy for ulcerative colitis. In: Inflammatory Bowel Diseases. 2007 ; Vol. 13, No. 3. pp. 284-290.
@article{92373e04ac174a76864a61fe6889a8e4,
title = "Extracorporeal elimination of TNF-α-producing CD14 dullCD16+ monocytes in leukocytapheresis therapy for ulcerative colitis",
abstract = "Background: In recent years leukocytapheresis using a leukocyte removal filter (known as lymphocytapheresis, LCAP) has been applied to the treatment of various autoimmune diseases including ulcerative colitis (UC). In the present study we aimed to clarify how LCAP therapy modifies inflammatory responses by modulating circulating TNF-α-producing monocytes. Methods: Mononuclear cells were obtained from blood before and after the first treatment, and the expression profiles of various immune cells (naive versus, memory, regulatory CD4+CD25bright versus non-regulatory CD4 +CD25- T cells, and CD14+CD16- versus CD14dullCD16+ monocytes) were assessed. To evaluate immunological differences between CD14+CD16- and CD14dullCD16+ monocytes, the expression of TNF-α, IL-6, IL-12, IL-10, IL-18, surface toll-like receptor 2 (TLR2), TLR4, and other activation markers including HLA-DR, CD80 and CD86, as well as cytokine profiles, were analyzed. Results: LCAP treatment selectively removed CD14 dullCD16+ monocytes, which preferentially produce TNF-α and IL-12 and express HLA-DR, CD80, CD86, and TLR2, compared with the major fraction of CD14+CD16- monocytes, which conversely produce a higher amount of IL-10. In addition, the CD4 +CD45RO+CD62L-/CD4+CD45RO +CD62L+ ratio was significantly lower after LCAP therapy. However, the CD4+CD25bright/total CD4+ ratio did not change. Conclusions: The present findings revealed the real target of proinflammatory CD14dullCD16+ monocytes removed during LCAP treatment of UC and that LCAP might be used as an extracorporeal anti-TNF-α therapy, expanding the clinical applications of this procedure to include the treatment of Crohn's disease.",
keywords = "CD14CD16 monocytes, Leukocytapheresis, Ulcerative colitis",
author = "Takanori Kanai and Shin Makita and Takahiro Kawamura and Yasuhiro Nemoto and Daisuke Kubota and Kazuyoshi Nagayama and Teruji Totsuka and Mamoru Watanabe",
year = "2007",
month = "3",
doi = "10.1002/ibd.20017",
language = "English",
volume = "13",
pages = "284--290",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Extracorporeal elimination of TNF-α-producing CD14 dullCD16+ monocytes in leukocytapheresis therapy for ulcerative colitis

AU - Kanai, Takanori

AU - Makita, Shin

AU - Kawamura, Takahiro

AU - Nemoto, Yasuhiro

AU - Kubota, Daisuke

AU - Nagayama, Kazuyoshi

AU - Totsuka, Teruji

AU - Watanabe, Mamoru

PY - 2007/3

Y1 - 2007/3

N2 - Background: In recent years leukocytapheresis using a leukocyte removal filter (known as lymphocytapheresis, LCAP) has been applied to the treatment of various autoimmune diseases including ulcerative colitis (UC). In the present study we aimed to clarify how LCAP therapy modifies inflammatory responses by modulating circulating TNF-α-producing monocytes. Methods: Mononuclear cells were obtained from blood before and after the first treatment, and the expression profiles of various immune cells (naive versus, memory, regulatory CD4+CD25bright versus non-regulatory CD4 +CD25- T cells, and CD14+CD16- versus CD14dullCD16+ monocytes) were assessed. To evaluate immunological differences between CD14+CD16- and CD14dullCD16+ monocytes, the expression of TNF-α, IL-6, IL-12, IL-10, IL-18, surface toll-like receptor 2 (TLR2), TLR4, and other activation markers including HLA-DR, CD80 and CD86, as well as cytokine profiles, were analyzed. Results: LCAP treatment selectively removed CD14 dullCD16+ monocytes, which preferentially produce TNF-α and IL-12 and express HLA-DR, CD80, CD86, and TLR2, compared with the major fraction of CD14+CD16- monocytes, which conversely produce a higher amount of IL-10. In addition, the CD4 +CD45RO+CD62L-/CD4+CD45RO +CD62L+ ratio was significantly lower after LCAP therapy. However, the CD4+CD25bright/total CD4+ ratio did not change. Conclusions: The present findings revealed the real target of proinflammatory CD14dullCD16+ monocytes removed during LCAP treatment of UC and that LCAP might be used as an extracorporeal anti-TNF-α therapy, expanding the clinical applications of this procedure to include the treatment of Crohn's disease.

AB - Background: In recent years leukocytapheresis using a leukocyte removal filter (known as lymphocytapheresis, LCAP) has been applied to the treatment of various autoimmune diseases including ulcerative colitis (UC). In the present study we aimed to clarify how LCAP therapy modifies inflammatory responses by modulating circulating TNF-α-producing monocytes. Methods: Mononuclear cells were obtained from blood before and after the first treatment, and the expression profiles of various immune cells (naive versus, memory, regulatory CD4+CD25bright versus non-regulatory CD4 +CD25- T cells, and CD14+CD16- versus CD14dullCD16+ monocytes) were assessed. To evaluate immunological differences between CD14+CD16- and CD14dullCD16+ monocytes, the expression of TNF-α, IL-6, IL-12, IL-10, IL-18, surface toll-like receptor 2 (TLR2), TLR4, and other activation markers including HLA-DR, CD80 and CD86, as well as cytokine profiles, were analyzed. Results: LCAP treatment selectively removed CD14 dullCD16+ monocytes, which preferentially produce TNF-α and IL-12 and express HLA-DR, CD80, CD86, and TLR2, compared with the major fraction of CD14+CD16- monocytes, which conversely produce a higher amount of IL-10. In addition, the CD4 +CD45RO+CD62L-/CD4+CD45RO +CD62L+ ratio was significantly lower after LCAP therapy. However, the CD4+CD25bright/total CD4+ ratio did not change. Conclusions: The present findings revealed the real target of proinflammatory CD14dullCD16+ monocytes removed during LCAP treatment of UC and that LCAP might be used as an extracorporeal anti-TNF-α therapy, expanding the clinical applications of this procedure to include the treatment of Crohn's disease.

KW - CD14CD16 monocytes

KW - Leukocytapheresis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=33947496270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947496270&partnerID=8YFLogxK

U2 - 10.1002/ibd.20017

DO - 10.1002/ibd.20017

M3 - Article

C2 - 17206704

AN - SCOPUS:33947496270

VL - 13

SP - 284

EP - 290

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 3

ER -